 RICHLAND, Wash., Sept. 28, 2021 GLOBE NEWSWIRE -- The American Brachytherapy Society ABS has recognized Isorays Cesium-131 in its recently released new consensus statement on the subject of low dose rate LDR prostate brachytherapy. This marks the first time Cesium-131 has been included in ABSs highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes following Cesium-131 prostate brachytherapy seeds have only recently been available. 